Prediction of locoregional extension and metastatic disease in prostate cancer: a review

Abstract Despite efforts to enhance the accuracy of prediction of extraprostatic disease, approximately 40% of the men undergoing radical prostatectomy are found at surgery to have non-organ-confined cancer. Predictive algorithms based on multivariate regression analysis and neural networks are widely available and are superior to our standard empirical methods of clinical staging. These algorithms have been validated in diverse and well-characterized patient groups. For enhancement of the predictive value, data input must be standardized and improved input variables must be incorporated. In addition to the three “classic” staging parameters, i.e., pretreatment prostate-specific antigen (PSA), biopsy pathology, and digital rectal examination, new variables now show promise in predicting disease extent and may be integrated in future predictive models. This review focuses on our present methods for prediction of locoregional spread and distant metastases in men with clinically localized prostate cancer.

[1]  E. Metter,et al.  Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.

[2]  D. Chan,et al.  Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. , 1998, The Journal of urology.

[3]  A. Partin,et al.  Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. , 1998, Critical reviews in clinical laboratory sciences.

[4]  T. Piironen,et al.  VARIOUS RATIOS OF HUMAN GLANDULAR KALLIKREIN (HK2) TO FREE AND TOTAL PSA IMPROVE DISCRIMINATION BETWEEN G1-G2 AND G3 PROSTATE TUMORS , 1999 .

[5]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[6]  J. Muscat,et al.  Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer , 1996, Abdominal Imaging.

[7]  A. Partin,et al.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. , 1999, Urology.

[8]  J. Oesterling,et al.  Update on the appropriate staging evaluation for newly diagnosed prostate cancer. , 1997, The Journal of urology.

[9]  J. Oesterling,et al.  Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. , 1993, Urology.

[10]  P. Narayan,et al.  Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer , 1994 .

[11]  P. Carroll,et al.  The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. , 1995, The Journal of urology.

[12]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[13]  Srinivasan Vijayakumar,et al.  Racial differences in prostate‐specific antigen levels in patients with local‐regional prostate cancer , 1992, The Prostate.

[14]  D. Grignon,et al.  College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. , 1995, Archives of pathology & laboratory medicine.

[15]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[16]  D. Grignon,et al.  College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. , 1995, Archives of pathology & laboratory medicine.

[17]  Manyak Mj,et al.  The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. , 1998 .

[18]  Hammond Eh,et al.  College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. , 1995 .

[19]  J. Oesterling,et al.  Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. , 1987, The Journal of urology.

[20]  F. Freiha,et al.  Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. , 1994, Urology.

[21]  A. Partin,et al.  Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients , 1999, Cancer.

[22]  R W Veltri,et al.  Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. , 1999, Urology.

[23]  M W Kattan,et al.  Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma , 1997, Cancer.

[24]  W. Catalona,et al.  Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. , 1994, The Journal of urology.

[25]  M. Kattan,et al.  VALIDATION OF A NOMOGRAM FOR PREDICTING DISEASE RECURRENCE FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER , 1999 .

[26]  D Faraggi,et al.  A neural network model for survival data. , 1995, Statistics in medicine.

[27]  D. Bostwick,et al.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. , 1994, The Journal of urology.

[28]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[29]  D. Bostwick,et al.  Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. , 1994, The Journal of urology.

[30]  P. Cuddy,et al.  Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models. , 1996, International journal of radiation oncology, biology, physics.

[31]  M. Manyak,et al.  The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. , 1998, Seminars in urologic oncology.

[32]  A W Partin,et al.  The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. , 1998, Seminars in urologic oncology.

[33]  ARTIFICIAL INTELLIGENCE SYSTEM IN PREDICTION OF LYMPH NODE INVOLVEMENT IN RADICAL PROSTATECTOMY PATIENTS , 1999 .

[34]  T. Reckwitz,et al.  The use of percent free PSA for early detection of prostate cancer. , 1999, Journal of andrology.

[35]  G G Klee,et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.

[36]  A. Hanlon,et al.  Analyzing predictive models following definitive radiotherapy for prostate carcinoma , 1997, Cancer.

[37]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[38]  A. Tewari,et al.  Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. , 1998, The Journal of urology.

[39]  K. Taari,et al.  Magnetic resonance imaging of clinically localized prostatic cancer. , 1998, The Journal of urology.

[40]  M. Kattan,et al.  VALIDATION OF THE PARTIN TABLES FOR PREDICTING PATHOLOGIC STAGE OF CLINICALLY CONFINED PROSTATE CANCER , 1999 .

[41]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.